ou sai hong 160 jpg

Sai-Hong I. Ou, MD, PhD

Specialties

Medical Oncology, Hematology-Oncology

Clinical Interests

lung cancer, thyroid cancer, clinical trials (early phase), targeted therapy

MyChart patient portal offers a convenient and secure way to manage your healthcare online. Use MyChart to schedule appointments, request prescription renewals, send messages to your care team and more.
Certifications
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology
Language
  • English
  • Cantonese
  • Mandarin
Gender
Male
Medical School
University of Texas Southwestern Medical School
Internship
Duke University School of MedicineCategorical Internal Med
Residency
Duke University School of MedicineInternal Medicine
Fellowship
Beth Israel Deaconess HospitalHematology/Oncology
Grad School
University of Texas Southwestern Medical Center — PhD, Cellular and Molecular Biology
Professional Positions
  • Professor — Division of Hematology/Oncology, Department of Medicine, UCI School of Medicine
  • Editor-in-Chief — Lung Cancer: Targets and Therapy
  • Associate Editor — Journal of Thoracic Oncology
Awards and Recognition
  • Best Doctors in America® (Medical Oncology and Hematology), 2011-2013
  • Young Investigator Award — Southwest Oncology Group (SWOG)
More Information

Dr. Sai-Hong I. Ou is board-certified UCI Health medical oncologist who specializes in the diagnosis and treatment of lung and thyroid cancers. He is an internationally renowned expert in targeted therapies for lung cancers.

He earned his medical degree at the University of Texas Southwestern Medical School in Dallas, followed by an internship and residency in internal medicine at Duke University School of Medicine in Durham, N.C. He received fellowship training in hematology/oncology at Beth Israel Deaconess Hospital in Boston, Mass. He also holds a PhD in cellular and molecular biology from the University of Texas Southwestern Medical Center in Dallas.

Ou is the author of more than 180 peer-reviewed manuscripts that have appeared in the New England Journal of Medicine, Lancet Oncology, the Journal of Clinical Oncology, Cancer Discovery and Nature Medicine, primarily about targeted therapies for lung cancer and resistance mechanisms.

He has conducted numerous early phase clinical trials that have advanced the standard of treatment for lung cancer care. In particular, he is one of the seven original principal investigators for a phase 1 clinical trial that led to the approval of crizotinib for the treatment of certain non-small cell lung cancers (NSCLC). His research also led to the approval of afatinib to treat certain NSCLCs. He also is actively collaborating with sequencing companies to mine data about resistance mechanisms, treatment outcomes to targeted therapy and rare actionable driver mutations.

Ou serves as editor-in-chief of Lung Cancer: Targets and Therapy and associate editor of the Journal of Thoracic Oncology. He is also an editorial board member for the Annals of Oncology, Critical Reviews in Oncology/Hematology, Clinical Lung Cancer and Translational Lung Cancer Research.

He sees patients at the UCI Health Chao Family Comprehensive Cancer Center in Orange.

Academic Profile

View this physician's faculty profile ›

Speakers Bureau Topics

  • ALK Positive Tumors (including lung cancer)
  • Esophageal Cancer
  • Gastric Cancer
  • Head and Neck Cancer
  • Lung Cancer in the Never Smoker
  • Lung Cancer Staging
  • Lung Cancer, New Driver Mutations
  • Lung Cancer, The Era of Molecularly Targeted Therapy
  • Molecular Profiling in Gastric and Cholangiocarcinoma Cancer
  • Nasopharyngeal Carcinoma
  • Non-Small Cell Lung Cancer
  • Second Generation Epidermal Growth Factor Receptor Inhibitor
  • Small Cell Lung Cancer
  • Stomach Cancer

UCI Health Chao Family Comprehensive Cancer Center
101 The City Drive South, Building 23
Orange, CA 92868
Phone: 714-456-8000
Fax: 855-211-3729